Fed Circ affirms invalidation of two cancer treatment patents

Judges uphold PTAB decision invalidating Incept patents related to use of biodegradable filler in radiation treatment | Swedish firm Palette had challenged patents through inter partes review.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotech

Regeneron and Amgen call a truce on two Eylea biosimilar patents

28 October 2026 Both companies have agreed to dismiss claims and counterclaims involving Amgen’s 2 mg aflibercept biosimilar, while their wider feud continues.

Biotech

10x and Parse set to end sequencing feud after appeals court defeat

23 October 2026 Following the Federal Circuit’s decision to uphold the invalidation of three patents, the parties are set to drop their remaining claims, despite 10x’s separate multi-million dollar jury win.

Biotech

Guardant loses second patent challenge to TwinStrand amid $245m damages fallout

16 October 2026 All 30 claims of a key DNA sequencing patent have been upheld for a second time, marking another setback in a long-running dispute that has already left Guardant facing a $245 million bill.

More features

LSPN Fall: AI agents are taking on patent work. What’s left for lawyers?

Dykema’s new trademark pro will be a ‘tremendous asset’ to clients

In-house counsel rethink patent filing strategies as costs mount

Fenwick hires NY partner to advise on regulatory matters

UK unveils £1bn sector investment push after recent setbacks

Justice Joanna Smith appointed to interim High Court role as Sir Colin Birss replaces Sir Geoffrey Vos

Oura targets Ultrahuman’s redesigned smart ring following import ban

Weil collapse leaves IP talent facing uncertain future after major expansion

Fed Circ affirms invalidation of two cancer treatment patents

More on this story

Editor's picks

Editor's picks

More features